Literature DB >> 28314380

Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy.

Ari J Wassner1, Rebecca H Jugo1, David M Dorfman2, Robert F Padera2, Michelle A Maynard1, Ann M Zavacki3, Patrick Y Jay4, Stephen A Huang1.   

Abstract

BACKGROUND: The thyroid hormone-inactivating enzyme type 3 deiodinase (D3) is induced during hypertrophic and ischemic cardiomyopathy, leading to a state of local cardiac hypothyroidism. Whether D3 induction occurs in dilated cardiomyopathy is unknown.
METHODS: This study characterized changes in cardiac D3 and thyroid hormone signaling in a transgenic model of progressive dilated cardiomyopathy (TG9 mice).
RESULTS: Cardiac D3 was dramatically induced 15-fold during the progression of dilated cardiomyopathy in TG9 mice. This D3 induction localized to cardiomyocytes and was associated with a decrease in myocardial thyroid hormone signaling.
CONCLUSIONS: Cardiac D3 is induced in a mouse model of dilated cardiomyopathy, indicating that D3 induction may be a general response to diverse forms of cardiomyopathy.

Entities:  

Keywords:  D3; cardiomyopathy; deiodinase; heart; heart failure

Mesh:

Substances:

Year:  2017        PMID: 28314380      PMCID: PMC5421592          DOI: 10.1089/thy.2016.0570

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  45 in total

1.  Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure.

Authors:  C Opasich; F Pacini; N Ambrosino; P G Riccardi; O Febo; R Ferrari; F Cobelli; L Tavazzi
Journal:  Eur Heart J       Date:  1996-12       Impact factor: 29.983

2.  Type 2 iodothyronin deiodinase transgene expression in the mouse heart causes cardiac-specific thyrotoxicosis.

Authors:  J Pachucki; J Hopkins; R Peeters; H Tu; S D Carvalho; H Kaulbach; E D Abel; F E Wondisford; J S Ingwall; P R Larsen
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

3.  Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction.

Authors:  Maria Giovanna Trivieri; Gavin Y Oudit; Rajan Sah; Benoit-Gilles Kerfant; Hui Sun; Anthony O Gramolini; Yan Pan; Alan D Wickenden; Walburga Croteau; Gabriella Morreale de Escobar; Roman Pekhletski; Donald St Germain; David H Maclennan; Peter H Backx
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-04       Impact factor: 11.205

4.  Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy.

Authors:  P Moruzzi; E Doria; P G Agostoni
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

Review 5.  Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state.

Authors:  Deborah D Ascheim; Katarzyna Hryniewicz
Journal:  Thyroid       Date:  2002-06       Impact factor: 6.568

6.  Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.

Authors:  Oliver Zolk; Thomas F Solbach; Thomas Eschenhagen; Alexander Weidemann; Martin F Fromm
Journal:  Biochem Biophys Res Commun       Date:  2008-09-07       Impact factor: 3.575

7.  Mice with hepatocyte-specific deficiency of type 3 deiodinase have intact liver regeneration and accelerated recovery from nonthyroidal illness after toxin-induced hepatonecrosis.

Authors:  Luciana A Castroneves; Rebecca H Jugo; Michelle A Maynard; Jennifer S Lee; Ari J Wassner; David Dorfman; Roderick T Bronson; Chinweike Ukomadu; Agoston T Agoston; Lai Ding; Cristina Luongo; Cuicui Guo; Huaidong Song; Valeriy Demchev; Nicholas Y Lee; Henry A Feldman; Kristen R Vella; Roy W Peake; Christina Hartigan; Mark D Kellogg; Anal Desai; Domenico Salvatore; Monica Dentice; Stephen A Huang
Journal:  Endocrinology       Date:  2014-07-08       Impact factor: 4.736

8.  Subclinical thyroid disorders in patients with dilated cardiomyopathy.

Authors:  F M Fruhwald; S Ramschak-Schwarzer; B Pichler; N Watzinger; M Schumacher; R Zweiker; W Klein; B Eber
Journal:  Cardiology       Date:  1997 Mar-Apr       Impact factor: 1.869

9.  A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase.

Authors:  Stephen A Huang; Stephanie A Fish; David M Dorfman; Domenico Salvatore; Harry P W Kozakewich; Susan J Mandel; P Reed Larsen
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression.

Authors:  Monica Dentice; Raffaele Ambrosio; Valentina Damiano; Annarita Sibilio; Cristina Luongo; Ombretta Guardiola; Siham Yennek; Paola Zordan; Gabriella Minchiotti; Annamaria Colao; Alessandro Marsili; Silvia Brunelli; Luigi Del Vecchio; P Reed Larsen; Shahragim Tajbakhsh; Domenico Salvatore
Journal:  Cell Metab       Date:  2014-11-13       Impact factor: 27.287

View more
  4 in total

Review 1.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

2.  Long-term prognostic value of combined free triiodothyronine and late gadolinium enhancement in nonischemic dilated cardiomyopathy.

Authors:  Kuo Zhang; Wenyao Wang; Shihua Zhao; Stuart D Katz; Giorgio Iervasi; A Martin Gerdes; Yi-Da Tang
Journal:  Clin Cardiol       Date:  2018-01-23       Impact factor: 2.882

3.  Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats.

Authors:  Kuo Zhang; Yi-Da Tang; Youhua Zhang; Kaie Ojamaa; Ying Li; Amandeep Singh Saini; Maria Alicia Carrillo-Sepulveda; Viswanathan Rajagopalan; A Martin Gerdes
Journal:  Thyroid       Date:  2018-05-07       Impact factor: 6.568

4.  Myocardium of patients with dilated cardiomyopathy presents altered expression of genes involved in thyroid hormone biosynthesis.

Authors:  Carolina Gil-Cayuela; Ana Ortega; Estefanía Tarazón; Luis Martínez-Dolz; Juan Cinca; José Ramón González-Juanatey; Francisca Lago; Esther Roselló-Lletí; Miguel Rivera; Manuel Portolés
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.